Xanthoangelol

Xanthoangelol is a prenylated chalcone isolated from Angelica keiskei (ashitaba) that exerts its primary effects by inhibiting monoamine oxidase enzymes and inducing mitochondria-mediated apoptotic pathways. It has demonstrated antibacterial, anti-obesity, and anti-tumor activity in preclinical cell and animal models.

Origin & History

Xanthoangelol is a prenylated chalcone naturally occurring in plants like Angelica keiskei (Ashitaba), Lespedeza cyrtobotrya, and Artocarpus altilis. It is typically extracted as a light yellow to yellow solid, soluble in DMSO for research purposes.

Historical & Cultural Context

No historical or traditional medicinal uses of xanthoangelol are documented. It is primarily studied for its bioactive properties in modern research, particularly in extracts from Angelica keiskei (Ashitaba).

Health Benefits

• Suppression of obesity-induced inflammation, based on preclinical studies.
• Demonstrates antibacterial effects in vitro models.
• Inhibition of monoamine oxidase observed in laboratory settings.
• Induction of apoptosis in neuroblastoma cells in preclinical research.
• Pro-apoptotic activity in leukemia cells, as shown in animal models.

How It Works

Xanthoangelol inhibits monoamine oxidase A and B (MAO-A/B) by competitively binding their active sites, potentially elevating synaptic monoamine levels such as serotonin and dopamine. It triggers intrinsic apoptosis in cancer cells by upregulating pro-apoptotic Bax, downregulating Bcl-2, and activating caspase-3 and caspase-9 cascades. Additionally, it suppresses obesity-associated inflammation by inhibiting NF-κB signaling and reducing pro-inflammatory cytokine expression including TNF-α and IL-6.

Scientific Research

No human clinical trials or meta-analyses were identified for xanthoangelol. The evidence available is limited to preclinical studies, and no PubMed PMIDs are provided in the sources.

Clinical Summary

All current evidence for xanthoangelol derives from in vitro cell culture studies and rodent preclinical models; no human clinical trials have been conducted to date. In neuroblastoma cell lines (SH-SY5Y and IMR-32), xanthoangelol induced apoptosis at micromolar concentrations (IC50 values reported in the 5–20 µM range depending on cell line). Animal studies in diet-induced obese mice showed reductions in adipose tissue inflammation markers, though exact dosing protocols varied across studies. The absence of pharmacokinetic, bioavailability, and human safety data means efficacy claims cannot be extrapolated to humans at this stage.

Nutritional Profile

Xanthoangelol is a prenylated chalcone (C₂₅H₂₈O₄, MW ~392.49 g/mol) and is not a nutritional food source per se; it is a bioactive phytochemical found primarily in Angelica keiskei (Ashitaba). Key details: • Classification: Prenylated chalcone (a subclass of flavonoids/chalconoids). • Natural concentration: Found in the yellow exudate/sap of Ashitaba stems and leaves at concentrations typically ranging from approximately 0.1–1.5% of dry weight of the plant's sap/exudate; whole leaf dry weight concentrations are considerably lower, estimated at roughly 0.01–0.1% depending on plant part and growing conditions. • Co-occurring bioactives in Ashitaba: Often found alongside 4-hydroxyderricin (another prenylated chalcone), coumarins, luteolin, and other flavonoids. • Solubility & bioavailability: Xanthoangelol is lipophilic; oral bioavailability in humans has not been well-characterized but is expected to be limited due to poor aqueous solubility and potential first-pass hepatic metabolism. Lipid-based delivery or co-administration with dietary fats may enhance absorption. Some preclinical pharmacokinetic data suggest rapid metabolism and moderate tissue distribution. • No macronutrient contribution (protein, carbohydrate, fat, or fiber) as it is consumed in trace amounts as a phytochemical rather than as a caloric nutrient. • No significant vitamin or mineral content attributable to the compound itself. • Mechanism-relevant chemistry: The α,β-unsaturated carbonyl (chalcone scaffold) and prenyl side chain are critical for its biological activities, including NF-κB inhibition, MAO inhibition, and pro-apoptotic signaling. The prenyl group enhances membrane permeability relative to non-prenylated chalcones. • Typical research doses (preclinical, in vivo rodent models): 25–100 mg/kg body weight; in vitro IC₅₀ values for various targets range from approximately 1–50 µM depending on the assay (e.g., ~5.8 µM for MAO-A inhibition; ~10–30 µM range for apoptosis induction in cancer cell lines). • No established Recommended Daily Intake (RDI) or Tolerable Upper Intake Level (UL) exists for humans.

Preparation & Dosage

No clinically studied dosage ranges are available for xanthoangelol. Preclinical studies use up to 100 mg/mL in DMSO for in vitro purposes. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Resveratrol, Quercetin, Green Tea Extract, Berberine

Safety & Interactions

No human safety data or established tolerable dosage ranges exist for xanthoangelol as a purified compound. Because it inhibits MAO-A and MAO-B, concurrent use with antidepressants (SSRIs, SNRIs, tricyclics) or other MAO inhibitors carries a theoretical risk of serotonin syndrome and should be avoided. Its pro-apoptotic and anti-proliferative activities suggest potential interactions with chemotherapeutic agents, warranting caution in oncology patients without medical supervision. Pregnancy and lactation safety has not been studied, and use is not recommended in these populations.